Take­da CEO Christophe We­ber fi­nal­ly clos­es on his $62B deal to buy Shire — now he has to con­vince share­hold­ers and slash jobs

Take­da CEO Christophe We­ber has fi­nal­ly closed his $62 bil­lion deal to buy out Shire. Now comes an even hard­er part.

The two com­pa­nies an­nounced the pact overnight, with Shire’s board ac­cept­ing We­ber’s of­fer of £49 a share, which val­ues the com­pa­ny at £46 bil­lion. Now he’ll have to sell it to share­hold­ers — which is not a giv­en af­ter Take­da saw its mar­ket cap plunge more than 20% dur­ing the talks.

Flem­ming Orn­skov

If he gets past that hur­dle We­ber will then need to knit to­geth­er a new top 10 — by sales — glob­al phar­ma com­pa­ny while carv­ing out $1.4 bil­lion in cost syn­er­gies. About $600 mil­lion will come out of two R&D or­ga­ni­za­tions that have al­ready been through sev­er­al cy­cles of re­struc­tur­ing. Slight­ly more than half will come from sales and ad­min­is­tra­tion.

That means job cuts.

Drill down in­to the fine print of the deal, and you’ll find that the top ex­ecs at Take­da will ax 6% to 7% of the com­bined work­force. About a third of that will come out of R&D, with the bulk of the cuts be­ing made to sales and ad­min­is­tra­tion. With about 30,000 staffers at Take­da and 22,000 at Shire, a 7% cut would cost the jobs of about 3,640 peo­ple.

The new Take­da that emerges will be based in Tokyo with ex­pand­ed op­er­a­tions in the Cam­bridge/Boston area, which will con­tain the bulk of its R&D group. The Japan­ese com­pa­ny says it will then start a re­view of fa­cil­i­ties, to see which Shire labs and of­fices will stay and which will go. Man­u­fac­tur­ing ops will al­so be in­te­grat­ed.

The new com­pa­ny will be left with re­gion­al groups in Japan, Sin­ga­pore, Switzer­land and the US. But Shire’s of­fi­cial head­quar­ters in Dublin, which will no longer be need­ed, may well face the ax.

The merg­er of these two com­pa­nies, with the small­er Take­da cap­tur­ing the larg­er prey, gives We­ber the glob­al trans­for­ma­tion he was asked to de­liv­er. But it al­so has raised se­ri­ous ques­tions about the longterm vi­a­bil­i­ty of the Shire or­ga­ni­za­tion he’s buy­ing, which has an ag­ing fran­chise in AD­HD and a ma­jor new threat to its he­mo­phil­ia op­er­a­tions from Roche’s Hem­li­bra. 

Un­der CEO Flem­ming Orn­skov, Shire bought out Bax­al­ta for $32 bil­lion, and has been com­bin­ing its drugs in­to a pipeline heav­i­ly fo­cused on rare dis­eases, giv­ing Take­da what it likes to call a com­ple­men­tary or­ga­ni­za­tion to its own con­cen­tra­tion on on­col­o­gy, gas­troen­terol­o­gy and cen­tral ner­vous sys­tem ther­a­peu­tic ar­eas plus vac­cines.

Thomas Dit­trich

Take­da al­so set aside $9.1 mil­lion for re­ten­tion bonus­es to keep the ser­vices of some key per­son­nel, which will dou­ble the pay and bonus­es due to CEO Orn­skov and CFO Thomas Dit­trich.

JP Mor­gan Chase Bank, Sum­it­o­mo Mit­sui Bank­ing Cor­po­ra­tion and MUFG Bank have put to­geth­er a $31 bil­lion bridge loan to com­plete the cash por­tion of the deal, which will lat­er be re­struc­tured in­to a longterm loan as Take­da tries to con­vince the cred­it rat­ing groups to show some mer­cy on its rat­ings.


Im­age: Christophe We­ber. GET­TY IM­AGES

Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)

Idor­si­a's brain bleed drug flunks PhI­II tri­al, a decade af­ter pre­vi­ous flop

Idorsia’s long journey with clazosentan came to an abrupt “unexpected result” Monday morning with a Phase III flop.

The Swiss biopharma said the drug did not meet the main goal of the late-stage REACT study, conducted in the US, Canada and Europe since early 2019.

The 409-patient trial tested the intravenous drug’s ability to prevent complications due to delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage (aSAH), in which blood vessels in the brain narrow and blood accumulates around the brain’s surface, which then dials up the pressure on the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.

Kenji Yasukawa, Astellas CEO (Photographer: Akio Kon/Bloomberg via Getty Images)

Astel­las taps chief strat­e­gy of­fi­cer as next CEO to 'go on the ag­gres­sive'

Five years into its big R&D revamp, Astellas says it’s time for a changing of the guard.

Kenji Yasukawa, who took over as president and CEO in 2018, will step down to become chairman of the board in April, making room for Naoki Okamura to take over. Okamura joined the company in 1986 and has served in a variety of finance, business and strategy roles, including most recently as chief strategy officer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.

Clin­i­cal tri­al di­ver­si­ty da­ta show mis­match be­tween en­roll­ment and dis­ease preva­lence, GSK says

A lack of diversity in clinical trials has persisted despite decades of initiatives to try to turn the tide.

In a recent review of 17 years of clinical trials, drugmaker GSK found that there were some mismatches between the demographics of its US-based trials and how prevalent diseases were in those populations.

The results, the company says, will help GSK and others design studies that better represent epidemiological rates within races and ethnicities.

The Big Phar­ma dis­card pile; Lay­offs all around while some biotechs bid farewell; New Roche CEO as­sem­bles top team; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

With earnings seasons in full swing, we’ve listened in on all the calls so you don’t have to. But news is popping up from all corners, so make sure you check out our other updates, too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.

Goldfinch Bio CEO Tony Johnson (L) and Karuna Therapeutics CEO Bill Meury

Karuna li­cens­es Goldfinch as­sets to com­pete with Boehringer In­gel­heim in neu­ro­science

Karuna Therapeutics is looking to compete with Boehringer Ingelheim on depression and anxiety with a new license to Goldfinch Bio’s assets, starting with $15 million to the shuttered biotech.

Karuna steps into an arena already being tested by Boehringer in multiple Phase II studies — the two are targeting transient receptor potential canonical 4 and 5, or TRPC4/5, which is thought to have a role in neuroscience indications. Goldfinch’s asset went through a Phase II in kidney diseases, but Karuna’s sights are set on mood and anxiety disorders for now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.

Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/Politico via AP Images)

In­fla­tion re­bates in­com­ing: Wyden calls on CMS to move quick­ly as No­var­tis CEO pledges re­ver­sal

Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes.

The newly signed Inflation Reduction Act requires manufacturers to pay a rebate to Medicare when they increase drug prices faster than the rate of inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.

Trodelvy notch­es a win in most com­mon form of breast can­cer

Following a promise last year to go “big and fast in breast cancer,” Gilead has secured a win for Trodelvy in the most common form.

The drug was approved to treat HR-positive, HER2-negative breast cancer patients who’ve already received endocrine-based therapy and at least two other systemic therapies for metastatic cancer, Gilead announced on Friday.

Trodelvy won its first indication in metastatic triple-negative breast cancer back in 2020, and has since added urothelial cancer to the list. HR-positive HER2-negative breast cancer accounts for roughly 70% of new breast cancer cases worldwide per year, according to senior VP of oncology clinical development Bill Grossman, and many patients develop resistance to endocrine-based therapies or worsen on chemotherapy.

Raymond Stevens, Structure Therapeutics CEO

Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

What does it take to pull off a $161 million biotech IPO these days?

In Structure Therapeutics’ case, it means having a star scientist co-founder paired with the computational drug discovery company Schrödinger, $198 million in private funding from blue-chip investors, almost six years of research work on G protein-coupled receptors and a slate of oral, small-molecule drugs, with an eye on the huge and growing diabetes and weight-loss market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.

Af­ter 13 years, Ramy Mah­moud steps in­to CEO seat at Opti­nose; Ru­pert Vessey set to ex­it Bris­tol My­ers in Ju­ly

After 13 years as president and COO at Optinose, Ramy Mahmoud has stepped into a new role as its CEO. He is taking the place of Peter Miller, who stepped down earlier this week, though Miller is still staying with the company as a consultant.

In 2010, the two business partners joined Optinose to take it in a new direction, transforming it from a delivery platform to product company. They previously worked together at Johnson & Johnson, when Miller was president at Janssen and Mahmoud headed medical affairs. Miller said after he learned about Optinose, “I did what I always do, which is find people smarter than me to talk with about the idea. And the first person I called was Ramy … and I said, ‘Hey, Ramy, what do you think of this technology?’”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.